Ortholevo, Inc.
Publicly observedLynnfield, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Lynnfield | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Ortholevo, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | P3HTBAK4HNC4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant6 Aug 2024Publicly observed
NIH SBIR/STTR award: Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture
USD 490,333.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant6 Aug 2024Publicly observed
NIH SBIR/STTR award: Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture
USD 504,601.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.